A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

NCT00082212 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Due to lack of sufficient efficacy.

Conditions

Ovarian Cancer

Interventions

BIOLOGICAL: Cetuximab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]